Avance Clinical

community rating (0 votes):

Description

Avance Clinical is the largest full-service Australian CRO delivering quality clinical trials with globally accepted data in Australia and New Zealand for international biotechs. They offer a range of services including pre-clinical, clinical monitoring, data management, eClinical solutions, safety and pharmacovigilance, medical writing, project management, statistics, and quality assurance. With over two decades of experience, Avance Clinical has a proven track record of providing fast, agile, and adaptive clinical research services to biotechnology companies. They have a strong focus on technology and use industry-leading platforms to support speed, communications, and regulatory compliance. Avance Clinical has a team of over 300 experienced CRO specialists who are dedicated to delivering world-class results and high-quality internationally accepted data for FDA and EMA review.

website

Reviews

No Reviews Yet

Be the first to review one of our webinars!

Upcoming Webinars

There are no upcoming webinars on this topic or publisher.

Previous Webinars

Healthcare > Clinical Trials

Psychedelics in Focus: Clinical Trials, Transformations and Regulations

Join us for an informative webinar as we delve into the world of psychedelic trials and the evolving regulatory landscape surrounding these transformative therapies. Explore the promising efficacy of psychedelics like psilocybin, MDMA, 5-methoxy-dimethyltryptamine, and ibogaine in treating conditions such as depression, PTSD, anxiety, and substance use disorder. During this webinar, we will examine the diverse mechanisms of action underlying these psychedelic compounds, discuss the important results observed in clinical trials, highlight the pivotal role of organizations like MAPS (Multidisciplinary Association for Psychedelic Studies) in shaping the regulatory landscape for psychedelic medicines, explore the pipeline of next-generation psychedelic medicines, and gain insights into the recent guidance issued by the US FDA and explore the regulatory pathways for the clinical study and approval of psychedelics in both Australia and the United States.